Clearside Biomedical, Inc. (CLSD)
NASDAQ: CLSD · Real-Time Price · USD
1.030
+0.020 (1.98%)
At close: Nov 4, 2024, 4:00 PM
1.070
+0.040 (3.88%)
After-hours: Nov 4, 2024, 5:34 PM EST
Clearside Biomedical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 7.52 | 8.23 | 1.33 | 29.58 | 7.89 | 2.17 | |
| Revenue Growth (YoY) | 365.02% | 519.89% | -95.51% | 274.65% | 263.28% | 7143.33% | |
| Cost of Revenue | 0.14 | 0.36 | 0.2 | - | - | - | |
| Gross Profit | 7.38 | 7.87 | 1.12 | 29.58 | 7.89 | 2.17 | |
| Selling, General & Admin | 11.49 | 11.87 | 11.77 | 11.67 | 10.76 | 16.82 | |
| Research & Development | 21.67 | 20.85 | 19.63 | 18.54 | 15.07 | 15.66 | |
| Operating Expenses | 33.15 | 32.72 | 31.4 | 30.2 | 25.83 | 32.48 | |
| Operating Income | -25.77 | -24.84 | -30.28 | -0.63 | -17.94 | -30.3 | |
| Interest Expense | -9.64 | -9.36 | -3.34 | - | -0.34 | -1.03 | |
| Interest & Investment Income | 1.54 | 1.72 | 0.67 | - | - | - | |
| Other Non Operating Income (Expenses) | 0.42 | - | - | 0.01 | 0.06 | 0.57 | |
| EBT Excluding Unusual Items | -33.46 | -32.49 | -32.95 | -0.62 | -18.21 | -30.77 | |
| Other Unusual Items | - | - | - | 1 | - | - | |
| Pretax Income | -33.46 | -32.49 | -32.95 | 0.38 | -18.21 | -30.77 | |
| Net Income | -33.46 | -32.49 | -32.95 | 0.38 | -18.21 | -30.77 | |
| Net Income to Common | -33.46 | -32.49 | -32.95 | 0.38 | -18.21 | -30.77 | |
| Shares Outstanding (Basic) | 67 | 62 | 60 | 58 | 47 | 38 | |
| Shares Outstanding (Diluted) | 67 | 62 | 60 | 60 | 47 | 38 | |
| Shares Change (YoY) | 10.50% | 2.66% | 0.50% | 28.81% | 21.84% | 24.20% | |
| EPS (Basic) | -0.50 | -0.53 | -0.55 | 0.01 | -0.39 | -0.81 | |
| EPS (Diluted) | -0.50 | -0.53 | -0.55 | 0.01 | -0.39 | -0.81 | |
| Free Cash Flow | -20.16 | -19.91 | -13.61 | -10.73 | -13.18 | -27.09 | |
| Free Cash Flow Per Share | -0.30 | -0.32 | -0.23 | -0.18 | -0.28 | -0.71 | |
| Gross Margin | 98.11% | 95.68% | 84.63% | 100.00% | 100.00% | 100.00% | |
| Operating Margin | -342.48% | -302.02% | -2281.61% | -2.12% | -227.20% | -1394.57% | |
| Profit Margin | -444.66% | -394.91% | -2482.82% | 1.27% | -230.68% | -1416.01% | |
| Free Cash Flow Margin | -267.89% | -242.06% | -1025.70% | -36.29% | -166.90% | -1246.80% | |
| EBITDA | -25.66 | -24.78 | -30.13 | -0.45 | -17.76 | -30.09 | |
| EBITDA Margin | - | - | - | -1.52% | -224.92% | - | |
| D&A For EBITDA | 0.11 | 0.07 | 0.15 | 0.18 | 0.18 | 0.21 | |
| EBIT | -25.77 | -24.84 | -30.28 | -0.63 | -17.94 | -30.3 | |
| EBIT Margin | - | - | - | -2.12% | -227.20% | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.